ATE102993T1 - Virale expressionsinhibitoren. - Google Patents

Virale expressionsinhibitoren.

Info

Publication number
ATE102993T1
ATE102993T1 AT88307302T AT88307302T ATE102993T1 AT E102993 T1 ATE102993 T1 AT E102993T1 AT 88307302 T AT88307302 T AT 88307302T AT 88307302 T AT88307302 T AT 88307302T AT E102993 T1 ATE102993 T1 AT E102993T1
Authority
AT
Austria
Prior art keywords
virus
dna
nucleic acid
acid sequence
viral expression
Prior art date
Application number
AT88307302T
Other languages
English (en)
Inventor
Elliot J Androphy
Douglas R Lowy
John T Schiller
Original Assignee
New England Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Inc filed Critical New England Medical Center Inc
Application granted granted Critical
Publication of ATE102993T1 publication Critical patent/ATE102993T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT88307302T 1987-08-07 1988-08-08 Virale expressionsinhibitoren. ATE102993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8377187A 1987-08-07 1987-08-07
EP88307302A EP0302758B1 (de) 1987-08-07 1988-08-08 Virale Expressionsinhibitoren

Publications (1)

Publication Number Publication Date
ATE102993T1 true ATE102993T1 (de) 1994-04-15

Family

ID=22180594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88307302T ATE102993T1 (de) 1987-08-07 1988-08-08 Virale expressionsinhibitoren.

Country Status (7)

Country Link
US (1) US5674835A (de)
EP (1) EP0302758B1 (de)
JP (1) JPH01137970A (de)
AT (1) ATE102993T1 (de)
CA (1) CA1339596C (de)
DE (1) DE3888425T2 (de)
ES (1) ES2061661T3 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
WO1991014790A1 (en) * 1990-03-27 1991-10-03 New England Medical Center Hospitals, Inc. Inhibitors of transcription activation activity of papillomaviruses
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
WO1993007299A1 (en) * 1991-10-11 1993-04-15 Cetus Oncology Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (de) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1998001148A1 (en) 1996-07-09 1998-01-15 President And Fellows Of Harvard College Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7261895B2 (en) * 2001-02-26 2007-08-28 Quattromed Ltd. Peptide tag for monitoring and purification of proteins
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
AU2003256325A1 (en) * 2002-06-26 2004-01-19 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
EP2567972A1 (de) 2011-09-12 2013-03-13 Adriacell S.p.A. Antikörper gegen das E7-Protein des Humanen Papillomvirus (HPV)
CN107266536A (zh) * 2017-06-27 2017-10-20 广州辉骏生物科技有限公司 一种用于质谱检测的蛋白封闭剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775630A (en) * 1986-08-15 1988-10-04 Vanderbilt University Transcriptional control element adapted for regulation of gene expression in animal cells

Also Published As

Publication number Publication date
JPH01137970A (ja) 1989-05-30
DE3888425T2 (de) 1994-06-23
ES2061661T3 (es) 1994-12-16
EP0302758A1 (de) 1989-02-08
EP0302758B1 (de) 1994-03-16
US5674835A (en) 1997-10-07
CA1339596C (en) 1997-12-23
DE3888425D1 (de) 1994-04-21

Similar Documents

Publication Publication Date Title
DE3888425T2 (de) Virale Expressionsinhibitoren.
PT87769A (pt) Transcripton-based nucleic acid amplification detection systems
DE3886710T2 (de) Verfahren zur selektiven inhibierung von hiv.
ATE191513T1 (de) Verfahren zur amplifikation von nukleinsäuren
DE3850093T2 (de) Verfahren zur Amplifizierung von Nukleinsäuren.
DE69028891D1 (de) Amplifikationsverfahren
ATE193726T1 (de) Spezifische nukleotidsequenz enthaltender masernvirusvakzinstamm und verfahren zu seiner absoluten identifizierung
ES468363A1 (es) Proceso para la fabricacion de un preparado destinado al tra-tamiento de herpes-zoster.
ATE337404T1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.
ATE88504T1 (de) Verfahren zur genetischen modifikation von pflanzen.
DE3850056D1 (de) Verfahren zur Regeneration von desaktivierten Mikroorganismen.
ATE67478T1 (de) Verfahren zur katalytischen dimerisierung von alkylacrylat.
DK277787D0 (da) Azaphospholener og deres anvendelse
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.
ATE99119T1 (de) Verfahren zur selektiven inhibierung von hiv.
ATE64678T1 (de) Verfahren zur beherrschung von unkraut.
ATE96029T1 (de) Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5- ethyluracil.
GB1411748A (en) Derivatives of double-stranded rna

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee